Edward Marcus, MD
Ophthalmology · New York, NYNPI 1841451937
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 24.3% of the total. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,193 payments — averaging $128.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$37K
- Alimera Sciences, Inc.$32K
- Astellas Pharma US Inc$26K
- AbbVie$9K
- Mallinckrodt Hospital Products Inc.$9K
- Bausch & Lomb Americas Inc.$7K
- plus $33K from 23 others
Across 17 payments — averaging $1849.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$22K
- Regeneron$10K
What the payments were for
- Consulting fees$43,68829%
- Speaking & faculty fees$79,91052%
- Travel & lodging$2,0701%
- Food & beverage$27,42418%
- Education$1830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 144 | $37,321 |
| Alimera Sciences, Inc. | 132 | $31,704 |
| Astellas Pharma US Inc | 58 | $25,637 |
| AbbVie(2 entities) | 121 | $9,253 |
| Mallinckrodt Hospital Products Inc. | 161 | $9,232 |
| Bausch & Lomb Americas Inc. | 81 | $7,494 |
| Novartis | 51 | $6,171 |
| Apellis Pharmaceuticals, Inc. | 61 | $5,857 |
| Eyepoint US, Inc. | 116 | $5,498 |
| Dutch Ophthalmic, USA | 7 | $3,331 |
| Novartis Pharma AG | 1 | $2,925 |
| ANI Pharmaceuticals, Inc. | 34 | $2,495 |
| Harrow Eye, LLC | 56 | $2,401 |
| Genentech USA, Inc. | 60 | $1,226 |
| Coherus Oncology, Inc. | 27 | $663 |
| Sandoz | 22 | $565 |
| Biotissue Holdings Inc. | 9 | $294 |
| Alcon | 4 | $287 |
| Mallinckrodt Enterprises LLC | 25 | $238 |
| Biogen | 9 | $228 |
| Rxsight Inc | 1 | $131 |
| Lensar, Inc. | 1 | $101 |
| Amgen | 4 | $72 |
| Sun Pharmaceutical Industries Inc. | 2 | $39 |
| Oyster Point Pharma, Inc. | 2 | $38 |
| Samsara Vision | 1 | $29 |
| Ocular Therapeutix, Inc. | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Notal Vision, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$30,737
- Izervay$24,512
- EYLEA HD$22,300
- YUTIQ$15,376
- EYLEA$12,267
- BEOVU$8,247
- OZURDEX$6,670
- ACTHAR$6,400
- XIPERE$5,940
- Syfovre$3,423
- EVA, combined machine$2,574
- EVA Ophthalmic Surgical System$734
- TRIESENCE$700
- TISSUEBLUE$324
- IHEEZO$171
- Clareon$146
- RXSIGHT CONTACT LENS$131
- RXSIGHT INJECTOR CARTRIDGE$131
- RXSIGHT INJECTOR HANDPIECE$131
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$131
How this compares
$153,275 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 22 | $33,666 |
| Prednisolone Acetate | 154 | $7,584 |
| Bromfenac Sodium | 35 | $6,186 |
| Atropine Sulfate | 123 | $5,917 |
| LumiganBimatoprost | 15 | $5,099 |
| Brimonidine Tartrate | 41 | $4,516 |
| Alphagan PBrimonidine Tartrate | 11 | $3,495 |
| Ofloxacin | 124 | $2,107 |
| Difluprednate | 17 | $2,053 |
| Dorzolamide Hcl | 90 | $1,280 |
| Latanoprost | 77 | $845 |
| Timolol Maleate | 28 | $781 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $9,253 | $42,26048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.